BioLife Solutions Stock (NASDAQ:BLFS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$24.07

52W Range

$9.92 - $26.73

50D Avg

$24.03

200D Avg

$20.80

Market Cap

$1.18B

Avg Vol (3M)

$309.83K

Beta

1.87

Div Yield

-

BLFS Company Profile


BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

409

IPO Date

Nov 22, 1989

Website

BLFS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$117.69M--
Service$17.55M--
Rental Revenue$8.03M$4.63M$14.80M
Service Revenue-$210.00K$108.00K

Fiscal year ends in Dec 23 | Currency in USD

BLFS Financial Summary


Dec 23Dec 22Dec 21
Revenue$143.27M$161.76M$119.16M
Operating Income$-70.83M$-39.91M$-30.37M
Net Income$-66.09M$-139.81M$-8.38M
EBITDA$-70.83M$-29.51M$-23.98M
Basic EPS-$-3.29$-0.22
Diluted EPS-$-3.29$-0.22

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 09, 24 | 8:36 PM
Q4 24Feb 29, 24 | 10:06 PM
Q4 23Feb 29, 24 | 12:00 AM

Peer Comparison


TickerCompany
COOThe Cooper Companies, Inc.
WSTWest Pharmaceutical Services, Inc.
ATRCAtriCure, Inc.
KRMDKORU Medical Systems, Inc.
AKYAAkoya Biosciences, Inc.
ATRIAtrion Corporation
ALCAlcon Inc.
RMDResMed Inc.
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
NSTGNanoString Technologies, Inc.
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.
TFXTeleflex Incorporated